Runt-related transcription factor 1 (RUNX1; also known as AML1) is a gene that codes for the alpha subunit of the core binding factor protein. This protein is thought to take part in regulating expression of multiple genes involved in normal hematopoiesis (Gene 2013; Kurokawa and Hirai 2003). RUNX1 is involved in translocations observed in hematologic malignancies, including AML, ALL, and myelodysplastic syndromes. Its role in cancer is also being investigated in promyelocytic leukemia, as well as in solid tumors such as endometrial, ovarian, and breast cancer. In addition, germline RUNX1 mutations, deletions, and translocations have been associated with conditions that predispose individuals to myeloid malignancies (Cazzola, Della Porta, and Malcovati 2013; Michaud et al. 2002; NCCN 2014; Song et al. 1999).

Runt-related transcription factor 1; translocated to, 1 (cyclin D-related), also known as RUNX1T1, is a gene that codes for a transcription-regulating protein (UniProt 2013). Other synonyms for RUNX1T1 include AML1T1, ETO, and MTG8. RUNX1T1’s role in AML is well documented. RUNX1T1 may also play a role in CML and other leukemias, as well as pancreatic and ovarian cancers.

The RUNX1-RUNX1T1 fusion has been primarily observed in acute myeloid leukemia.


Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S.

Suggested Citation: Seegmiller, A., Jagasia, M. 2014. RUNX1-RUNX1T1. My Cancer Genome (Updated September 2014)

Modified: September 10, 2014

Disclaimer: The information presented at is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.